A2W Pharma

What A2W Pharma does

A2W Pharma Ltd is a Malta-based pharmaceutical contract development and manufacturing organization (CDMO) founded in 2019 as a subsidiary of Amino Chemicals, focused on medical and pharmaceutical cannabis products. The company operates from a single facility in the Marsa Industrial Estate and serves B2B customers including pharmaceutical companies, medical cannabis businesses, and nutraceutical companies that require GMP-compliant manufacturing and formulation expertise for cannabinoid-based products.

The company's core technical capabilities span four integrated areas: (1) in-house chemical and microbiological quality testing using GC-MS, LC-MS/MS, ICP-MS, HPLC, and GC methods, with dedicated stability chambers; (2) supercritical CO2 extraction with tunable selectivity via temperature and pressure control for targeted compound isolation; (3) EU GMP-compliant processing and filling lines for liquid formulations, supported by SCADA PLC automation and CFR21 Part 11 digital compliance; and (4) a dedicated R&D lab that leverages group-level capabilities including ABA Chemical's Shanghai facility and research partners in Canada and the US. Together these capabilities form a complete development chain from pre-formulation through finished product.

A2W Pharma generates revenue through professional services-style contract manufacturing, with contact-based quoting and no public pricing disclosed. Go-to-market is executed via direct B2B enterprise sales supplemented by active presence at major industry events including CPHI Worldwide, Expopharm, ICBC, and Vitafoods Europe. The company maintains EU GMP and CFR21 Part 11 certifications, GDPR compliance, and is a member of the UK Cannabis Industry Council (since October 2023). No external institutional investors or funding rounds are disclosed; the company operates as a privately held subsidiary under Amino Chemicals.

Name

A2W Pharma

Legal name

A2W Pharma Ltd

Website

https://a2wpharma.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

A2W Pharma Ltd is a Malta-based pharmaceutical CDMO founded in 2019 as a subsidiary of Amino Chemicals, providing EU GMP-compliant contract manufacturing, supercritical CO2 extraction, in-house quality testing, and R&D services for medical and pharmaceutical cannabis products to B2B pharmaceutical, cannabis, and nutraceutical companies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical contract manufacturing
• Cannabis extraction services
• GMP manufacturing services
• Cannabinoid API development
• Supercritical CO2 extraction

Headquarters

HQ city

Marsá

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Contract Manufacturing Services: A2W Pharma provides contract manufacturing services for pharmaceutical and medical cannabis products, offering the complete development chain from pre-formulation to formulation, including GMP processing and quality testing services.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

A2W Pharma provides contract manufacturing and pharmaceutical development services for medical and pharmaceutical cannabis products. Its capabilities span supercritical CO2 extraction, EU GMP-compliant liquid formulation processing and filling, full chemical and microbiological quality testing, and dedicated R&D services for cannabinoid API process development and formulation.

Product overview

A2W Pharma is a pharmaceutical company established in 2019 by Amino Chemicals, offering a unified portfolio of cannabis-based pharmaceutical development services. The company's core offerings include Full Chemical and Microbiological Quality Testing (using GC-MS, LC-MS/MS, ICP-MS, HPLC, GC), Super Critical CO2 Extraction (a tunable extraction technology), GMP Processing and Filling Lines (EU GMP-compliant liquid formulation production), and Dedicated R&D Lab Services. These services work together to provide complete pharmaceutical development from raw material through finished product, with the Medical and Pharmaceutical Cannabis Solutions serving as the overarching service for bridging pharmacology and medicine with access to cannabis plant benefits.

Differentiator

Problem solved

Functional benefit

Products and services

• Full Chemical and Microbiological Quality Testing In-house quality control laboratory providing comprehensive chemical testing using GC-MS, LC-MS/MS, ICP-MS, HPLC, and GC methods, along with fully compliant microbiology testing. Manages its own stability chambers for ongoing and accelerated studies, offering complete process control from raw biological material through finished products without third-party outsourcing.
• Super Critical CO2 Extraction Extraction service using supercritical fluid technology with CO2 as solvent. Selectivity can be adjusted by varying temperature and pressure to obtain fractions containing specific compounds, enabling targeted production of high-value cannabis extracts for pharmaceutical applications.
• GMP Processing and Filling Lines EU GMP-compliant manufacturing service producing high-quality liquid formulations with fully automated equipment connected to state-of-the-art SCADA PLC systems for full process control and CFR21 Part 11 compliance.
• Dedicated R&D Lab Services Research and development services leveraging the group's technical capabilities including ABA Chemical's R&D facility in Shanghai and research partners in Canada and the US, focused on process development, analytical development, pre-formulation testing, and process troubleshooting.
• Medical and Pharmaceutical Cannabis Solutions End-to-end pharmaceutical development services bridging pharmacology and medicine, including API process development, GMP compliance, regulatory support, and innovative routes to target cannabinoid molecules for successful pharmaceutical formulation launches.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Cannabis Industry Council (CIC)coreStrategic or Co-development Partner · 1 October 2023A2W Pharma officially joined the Cannabis Industry Council (CIC), the leading membership organization for the UK cannabis industry, in October 2023. The partnership aligns A2W's mission with CIC's goals of improving accessibility to cannabis, betterment of people's wellbeing, environmental sustainability, and economic prosperity.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Others

• Almac Group: Global pharmaceutical CDMO offering formulation development, analytical services and GMP manufacturing — comparable operating model to A2W at greater scale but without cannabis specialization, positioning it as a competitive CDMO option for non-cannabis-heavy work.

Emerging players

• Incannex Healthcare: Australia-based clinical-stage pharmaceutical company developing cannabinoid-based prescription medicines (e.g., IHL-42X for OSA), with formulation and clinical development focus mirroring A2W's R&D-driven model.
• Demetrix: US-based cannabinoid pharmaceutical startup (backed by Danone and Gotham Green) focused on producing rare cannabinoids via fermentation for pharmaceutical applications — adjacent in pharma-grade cannabinoid API development.
• Avextra (formerly EuroCann / Solstice): German-headquartered medical cannabis supplier with EU GMP cultivation and processing plus a pharmaceutical pipeline of cannabinoid-based medicines — most directly comparable European specialty player in A2W's niche.

Broad incumbents

• Jazz Pharmaceuticals (GW Pharmaceuticals): Owner of Epidiolex (cannabidiol), the first FDA-approved plant-derived cannabinoid prescription drug. Operates a fully integrated cannabinoid pharmaceutical platform that overlaps with A2W's target market from a customer-or-competitor standpoint.
• Aurora Cannabis: Large Canadian cannabis producer with EU GMP-certified facilities and growing pharmaceutical-grade cannabinoid output, particularly in Germany — overlapping with A2W's European medical cannabis customer base.
• Tilray Brands: Global cannabis operator with pharmaceutical-grade GMP manufacturing in Portugal and Germany producing cannabinoid APIs and finished dose formats. Competes for the same enterprise cannabinoid pharma contracts A2W targets, with materially greater scale.
• Canopy Growth: Canadian cannabis operator with EU GMP-validated manufacturing and a Spectrum Therapeutics medical cannabis franchise, providing in-house extraction and formulation that competes with third-party CDMOs like A2W.
• Cronos Group: Cannabis operator with a biopharmaceutical strategy and GMP manufacturing capability, pursuing cannabinoid-based prescription therapeutics via partnerships such as its arrangement with Ginkgo Bioworks — comparable upstream/downstream.

Direct peers

• MediPharm Labs: Canadian-headquartered cannabis pharmaceutical CDMO offering GMP extraction, processing and formulation services to cannabis producers globally. Closest direct comparable to A2W in terms of pharma-grade contract manufacturing of cannabinoid APIs.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/a2w-pharma-ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about A2W Pharma